
10x Genomics, Inc. (TXG) Q4 2025 Earnings Call Transcript
TXG • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold TXG in your mock portfolio yet.
The negative EPS and PE ratio indicate that 10X Genomics remains unprofitable, with current earnings not supporting the valuation on a traditional basis. While the company may still be in a growth and investment phase, the lack of profitability and negative earnings profile are headwinds for the stock, especially in a higher-rate environment. Without clear evidence of a near-term path to positive net income, the financial picture leans negative from a pure fundamentals standpoint.
Despite an 11.7% decline over the last month, 10X Genomics is trading above its 200-day moving average, indicating that the longer-term trend is still constructive relative to recent history. The RSI around 58 suggests neither overbought nor oversold conditions, implying the recent pullback is more of a consolidation than a capitulation. Overall, technicals point to a mixed setup: some longer-term strength but near-term pressure and no clear momentum signal.
Alternative data points to a healthy and possibly expanding business footprint, with rising job openings and steady-to-growing professional engagement. The 10.9% month-over-month increase in job postings suggests ongoing investment in growth, R&D, or commercial capacity. LinkedIn follower growth and stable web traffic support the view that 10X Genomics maintains strong brand visibility and interest in its niche.
10X Genomics presents a mixed picture: structurally unprofitable today but showing signs of operational and ecosystem growth. Technicals are not signaling extreme risk or opportunity, while alternative data hints at ongoing business expansion and engagement. Overall, the balance of negative current earnings and positive growth signals supports a neutral stance on the stock at this time.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: